A pilot study co-authored by Hudson Founder Dr. Jonathann Kuo reveals the safety and efficacy of stem cell exosomes for lumbar facet joint pain.
Dr. Kuo, founder and Chief Medical Officer of Hudson Medical, recently co-authored a pilot study assessing the efficacy of treating lumbar facet joint pain (lower back joint pain) with bone marrow-derived mesenchymal stem cell exosomes.Â
You can explore the safety and efficacy results of this study here.
Over the course of the 3-month study, 20 adults were injected with bone marrow-derived mesenchymal stem cell exosomes, and their progress was assessed via regular in-office and virtual check-ins.Â
The pilot study found that the injections did not spur adverse effects in the patient sample, indicating the safety of bone marrow-derived stem cell exosomes.
Further, the group experienced significant progress across severity, interference, and disability indices. Here’s a breakdown of their average score improvements across each index:
| Index | Improvement |
| Severity | 65.04% |
| Interference | 72.09% |
| (Oswetstry) Disability | 58.43% |
To build on the promising results of this pilot study, Hudson and Dr. Kuo will continue to participate in groundbreaking research that explores the therapeutic potential of exosomes.Â
Congratulations to Dr. Kuo and his co-authors on this groundbreaking study.